ZJYL
Jin Medical·NASDAQ
--
--(--)
--
--(--)
8.15 / 10
Outperform
The stock's fundamentals show excellent quality (8.2/10). Favorable features: ROA (%) and Annualized net profit margin on total assets (%). Analytical stance: superior.
Analysis Checks(5/5)
ROA (%)
Value2.79
Score3/3
Weight31.40%
1M Return1.50%
Value2.79
Score3/3
Weight31.40%
1M Return1.50%
Total profit / EBIT (%)
Value197.81
Score2/3
Weight-25.14%
1M Return-1.47%
Value197.81
Score2/3
Weight-25.14%
1M Return-1.47%
EBIT / Total operating revenue (%)
Value3.90
Score3/3
Weight31.49%
1M Return1.51%
Value3.90
Score3/3
Weight31.49%
1M Return1.51%
Net cash flow from operating activities / Operating revenue (%)
Value14.04
Score3/3
Weight30.84%
1M Return1.44%
Value14.04
Score3/3
Weight30.84%
1M Return1.44%
Annualized net profit margin on total assets (%)
Value2.79
Score3/3
Weight31.40%
1M Return1.50%
Value2.79
Score3/3
Weight31.40%
1M Return1.50%
ROA (%)
Value2.79
Score3/3
Weight31.40%
1M Return1.50%
Value2.79
Score3/3
Weight31.40%
1M Return1.50%
Net cash flow from operating activities / Operating revenue (%)
Value14.04
Score3/3
Weight30.84%
1M Return1.44%
Value14.04
Score3/3
Weight30.84%
1M Return1.44%
Total profit / EBIT (%)
Value197.81
Score2/3
Weight-25.14%
1M Return-1.47%
Value197.81
Score2/3
Weight-25.14%
1M Return-1.47%
Annualized net profit margin on total assets (%)
Value2.79
Score3/3
Weight31.40%
1M Return1.50%
Value2.79
Score3/3
Weight31.40%
1M Return1.50%
EBIT / Total operating revenue (%)
Value3.90
Score3/3
Weight31.49%
1M Return1.51%
Value3.90
Score3/3
Weight31.49%
1M Return1.51%
Is ZJYL fundamentally strong?
- ZJYL scores 8.15/10 on fundamentals and holds a Discounted valuation at present. Backed by its 4.10% ROE, 6.68% net margin, 12.16 P/E ratio, 0.49 P/B ratio, and -50.00% earnings growth, these metrics solidify its Outperform investment rating.
